🇧🇪 UCB has started construction on its new R&D centre in Braine-l'Alleud, named Arkelia. This new facility represents an investment of over 100 million euros and is expected to be fully operational by mid-2028. @ucb_news

LiveDrop has launched the commercialisation of the new ModaFlow 4L5C, Revolutionising biotherapeutic discovery with picoscale droplet technology.

UCB partners with Ailux Biologics, a division of XtalPi, on biologics AI platform.

neuroClues has received MDR certification to market its early detection device for neurodegenerative diseases in Europe.

@TelixPharma it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses on-site from 2025.

@bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial.

IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site. @IBA_RadioPharma @IRE_IRE_ELiT

Looking for funding to support your research on #RareDiseases? A new European funding opportunity has been launched to support collaborative research on rare diseases under the Horizon Europe program.

RT @GossetOlivier1: La société liégeoise PDC*line Pharma a enregistré de bons résultats cliniques en phase I/II avec son vaccin thérapeutiq…

Hyloris Pharmaceuticals announces partnership with Rosemont Pharmaceuticals for Valacyclovir Oral Suspension in the U.S.

@QbDGroup announces acquisition of SciencePharma, strengthening global regulatory and quality expertise.

Wallonia leads in cancer innovation, with top companies in ATMPs, nuclear medicine, immunotherapy, precision medicine, and proton therapy, supported by exceptional academics and clinicians. A prime opportunity for investors to align impact with profit.

This call launched by BioWin is made for you! Grants offered range from 40% to 80%, depending on your company's size, for budgets between 1 to 4 million euros 💥

EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field.

Important new milestone for Novadip's NVDX3 securing IND approval from the FDA to initiate a phase 2b/3 study in cervical spine fusion.

Welcome to our new member Farbridge Pharma Consulting, a US-based consulting firm specialized in Quality Assurance.

atbtherapeutics has just closed a €54 million Series A financing round to propel innovative antibody payload technology into clinical development. This is one of the biggest fund-raisings in the life sciences sector in Belgium at such an early stage.

@OsivaxVaccines announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836.

🇧🇪 Belgium’s innovative biopharmaceutical sector invests 7x more in R&D compared to the EU27 average. With a daily investment of €15.5 million, Belgium has solidified its position as a European leader in pharmaceutical research and development.

Wonder who’s pitching at HealthTech Investor Summit this December? Or which European investors will be listening in? On the dedicated HTIS website, you’ll find both, plus the speakers and program. BioWin members get a 15% discount on all pitching.